68180-151 : Mirabegron 25 mg Oral Tablet, Film Coated, Extended Release
| NDC: | 68180-151 |
| Labeler: | Lupin Pharmaceuticals, Inc. |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Mirabegron |
| Dosage Form: | Oral Tablet, Film Coated, Extended Release |
| Application #: | ANDA209485 |
| Rev. Date: |
NDC Package Codes:
- 68180-151-06: 1 BOTTLE IN 1 CARTON (68180‑151‑06) / 30 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE
- 68180-151-09: 1 BOTTLE IN 1 CARTON (68180‑151‑09) / 90 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE
Active Ingredients:
- Mirabegron
Dosage Strength:
- 25 mg
Pharmaceutical Classes:
- Adrenergic beta3-Agonists [MoA]
- Cytochrome P450 2D6 Inhibitors [MoA]
- Cytochrome P450 3A Inhibitors [MoA]
- P-Glycoprotein Inhibitors [MoA]
- beta3-Adrenergic Agonist [EPC]
Related Products:
Based on records with the same trade name.- 70710-1159 Mirabegron 25 mg Oral Tablet, Extended Release by Zydus Pharmaceuticals (Usa) Inc.
- 70710-1160 Mirabegron 50 mg Oral Tablet, Extended Release by Zydus Pharmaceuticals (Usa) Inc.
- 70771-1752 Mirabegron 25 mg Oral Tablet, Extended Release by Zydus Lifesciences Limited
- 70771-1753 Mirabegron 50 mg Oral Tablet, Extended Release by Zydus Lifesciences Limited
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 68180-150Next: 68180-153 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.